Synthetic cartilage developer Biomimedica nears $14.2M VC goal

We've been hearing for a while now (and at BIO here in Boston) that venture funding for life sciences startups remains a struggle. But Biomimedica is the latest company to buck that trend. The South San Francisco company is heading toward the finish line in its push to raise $14.2 million in new financing, according to a regulatory filing.

As some investors told me during the conference this week, device startups are still drawing funding if they can offer something new that truly improves clinical care, provide great clinical data and if the product's developmental and regulatory costs aren't too overwhelming.

Perhaps that's the case with Biomimedica, which launched in 2007, according to MedCity News. So far, the company has raised $11.9 million from 10 different investors, including Emergent Medical Partners and Life Sciences Angels, according to the story. Biomimedica's technology spins out of Stanford University.

And the company's area of focus has a true need for new products. With a focus on osteoarthritis, Biomimedica is developing synthetic cartilage to be used for joint repairs. Patients are envisioned to use the product with an earlier intervention. Over time, osteoarthritis can lead to lesions and painful bone spurs.

- here's Biomimedica's regulatory filing
- read the MedCity News story here

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

Baxter has received clearance from the FDA for the latest version of its automated peritoneal dialysis system designed for home use.

Like AstraZeneca, Bayer and Sanofi before it, Bristol Myers Squibb has now tapped molecule modeler Schrödinger for a drug discovery collaboration.